These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30318176)

  • 21. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
    Guan H; Sheng Y; Guo W; Han S; Shi L
    Adv Ther; 2019 May; 36(5):1114-1125. PubMed ID: 30900201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
    Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
    Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
    Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
    Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
    Serritella AV; Bestvina CM
    Thorac Surg Clin; 2020 May; 30(2):137-146. PubMed ID: 32327172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
    Burudpakdee C; Wong W; Seetasith A; Corvino FA; Yeh W; Gubens M
    Lung Cancer; 2018 May; 119():103-111. PubMed ID: 29656744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
    Sacdalan DB; Lucero JA
    Cancer Treat Res Commun; 2021; 27():100319. PubMed ID: 33515938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T; Hida T; Yatabe Y
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K; Naruse I; Shimizu K; Asao T
    J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib: 
A Case Report and Literature Review].
    Yang H; Zhu W
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):673-676. PubMed ID: 34521190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC.
    Huang X
    J Exp Clin Cancer Res; 2018 Feb; 37(1):33. PubMed ID: 29463284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V; Pérol M
    Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V; Ou SH
    Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of ALK Inhibitors in Patients With
    Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alectinib in crizotinib-resistant, ALK-positive NSCLC.
    Jassem J
    Lancet Oncol; 2016 Feb; 17(2):134-135. PubMed ID: 26708154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.